Toxins 2016, 8(3), 78; https://doi.org/10.3390/toxins8030078
Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain
Jennifer R. Deuis 1,2, Joshua S. Wingerd 1, Zoltan Winter 3
, Thomas Durek 1, Zoltan Dekan 1, Silmara R. Sousa 1, Katharina Zimmermann 3, Tali Hoffmann 3, Christian Weidner 3, Mohammed A. Nassar 4, Paul F. Alewood 1, Richard J. Lewis 1 and Irina Vetter 1,2,*
, Thomas Durek 1, Zoltan Dekan 1, Silmara R. Sousa 1, Katharina Zimmermann 3, Tali Hoffmann 3, Christian Weidner 3, Mohammed A. Nassar 4, Paul F. Alewood 1, Richard J. Lewis 1 and Irina Vetter 1,2,*
1
Centre for Pain Research, Institute for Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia
2
School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia
3
Department of Physiology and Pathophysiology and Department of Anaesthesiology, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany
4
Department of Biomedical Science, University of Sheffield, Sheffield S10 2TN, UK
*
Author to whom correspondence should be addressed.
Academic Editors: Rong Chen and Yingliang Wu
Received: 25 January 2016 / Revised: 8 March 2016 / Accepted: 10 March 2016 / Published: 17 March 2016
(This article belongs to the Special Issue Animal Toxins and Biological Ion Channels)
Abstract
Loss-of-function mutations of NaV1.7 lead to congenital insensitivity to pain, a rare condition resulting in individuals who are otherwise normal except for the inability to sense pain, making pharmacological inhibition of NaV1.7 a promising therapeutic strategy for the treatment of pain. We characterized a novel mouse model of NaV1.7-mediated pain based on intraplantar injection of the scorpion toxin OD1, which is suitable for rapid in vivo profiling of NaV1.7 inhibitors. Intraplantar injection of OD1 caused spontaneous pain behaviors, which were reversed by co-injection with NaV1.7 inhibitors and significantly reduced in NaV1.7−/− mice. To validate the use of the model for profiling NaV1.7 inhibitors, we determined the NaV selectivity and tested the efficacy of the reported NaV1.7 inhibitors GpTx-1, PF-04856264 and CNV1014802 (raxatrigine). GpTx-1 selectively inhibited NaV1.7 and was effective when co-administered with OD1, but lacked efficacy when delivered systemically. PF-04856264 state-dependently and selectively inhibited NaV1.7 and significantly reduced OD1-induced spontaneous pain when delivered locally and systemically. CNV1014802 state-dependently, but non-selectively, inhibited NaV channels and was only effective in the OD1 model when delivered systemically. Our novel model of NaV1.7-mediated pain based on intraplantar injection of OD1 is thus suitable for the rapid in vivo characterization of the analgesic efficacy of NaV1.7 inhibitors. View Full-TextKeywords:
OD1; NaV1.7; PF-04856264; CNV1014802; raxatrigine; GpTx-1; pain
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Deuis, J.R.; Wingerd, J.S.; Winter, Z.; Durek, T.; Dekan, Z.; Sousa, S.R.; Zimmermann, K.; Hoffmann, T.; Weidner, C.; Nassar, M.A.; Alewood, P.F.; Lewis, R.J.; Vetter, I. Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain. Toxins 2016, 8, 78.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.